Targeting <i>KRAS</i>-Mutated NSCLC: Novel TKIs and Beyond-Reference-Cited by-同舟云学术

Targeting KRAS-Mutated NSCLC: Novel TKIs and Beyond

Published:2023-07-19 Issue:18 Volume:29 Page:3563-3565
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:

Author:

Cantor David J.¹^ORCID,Aggarwal Charu¹²³^ORCID

Affiliation:

1. 1Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

2. 2Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.

3. 3Penn Center for Cancer Care Innovation, University of Pennsylvania, Philadelphia, Pennsylvania.

Abstract

Summary KRAS-mutated non–small cell lung cancer (NSCLC) is the most common genetically altered subtype of NSCLC, yet targeted therapies remain limited. Multiple studies have investigated combinations of MEK inhibitors with chemotherapy without success. Here we discuss these studies and novel approaches to targeting KRAS-mutated NSCLC. See related article by Gadgeel et al., p. 3641

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Link

https://aacrjournals.org/clincancerres/article-pdf/doi/10.1158/1078-0432.CCR-23-1658/3348687/ccr-23-1658.pdf

Reference17 articles.

1. Phase II study of docetaxel and trametinib in patients with KRAS mutation positive recurrent non–small cell lung cancer (NSCLC) (SWOG S1507, NCT-02642042);Gadgeel;Clin Cancer Res,2023

2. The improbable targeted therapy: KRAS as an emerging target in non–small cell lung cancer (NSCLC);Salgia;Cell Rep Med,2021

3. A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non–small cell lung cancer (NSCLC);Blumenschein;Ann Oncol,2015

4. Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS-mutant advanced non–small cell lung cancer: the SELECT-1 randomized clinical trial;Jänne;JAMA,2017

5. Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor;Janes;Cell,2018